AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03819530 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin and Mineral Powder
Description: Vitamin and mineral nutritional supplement. Each packet is 1g of powder, to be taken with food.
Study NCT03992248 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time restricted feeding
Description: Eating within a time frame of 10hrs during the day. Outside of this time frame, participants need to refrain from food and energy containing drinks.
Study NCT03992248 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control
Description: Eating for at least 14hrs per day.
Study NCT00638560 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C, Vitamin E
Description: Vitamin C, 1g po, twice daily Vitamin E, 400 IU po, once daily
Study NCT00638560 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Antioxidant treatment
Description: no treatment
Study NCT00789867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pGM169/GL67A
Description: Received a nebulized dose via an breath-actuated nebulizer
Study NCT04727203 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AHAA
Description: Multi-component healthy lifestyle program
Study NCT04035850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine Tablets
Description: Strength 5-20 mg
Study NCT00726622 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open laparotomy and rectal resection
Description: Patients undergo open laparotomy and rectal resection.
Study NCT00726622 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted rectal resection
Description: Patients undergo laparoscopic-assisted rectal resection.
Study NCT01782365 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM stimulation
Description: no stimulation
Study NCT01782365 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 0,75 Hz stimulation
Study NCT05747508 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: INOpulse®
Description: Patients will be treated by means of an INOpulse® device using an INOpulse® nasal cannula
Study NCT05747508 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will be treated by means of an INOpulse® device using an INOpulse® nasal cannula
Study NCT05747508 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Long Term Follow Up
Description: Patients will be treated by means of an INOpulse® device using an INOpulse® nasal cannula
Study NCT03808688 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Netarsudil Ophthalmic Solution 0.02%
Description: 1 drop in each eye once daily in the evening
Study NCT00627029 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care Coordination
Description: Depending on the demonstration site, may consist of nurse telephonic counseling and monitoring, nurse in-person or home visits, home telemonitoring equipment, patient educational materials, patient group educations classes, physician education and feedback.
Study NCT04389190 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluoroscopy settings for image acquisition
Description: X-ray radiation is routinely used for imaging in coronary cath labs. Intervention involves lowering patient and operators X-ray exposure by employing various setting on the fluoroscopy machine.
Study NCT04389190 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fluoroscopy settings for image acquisition
Description: X-ray radiation is routinely used for imaging in coronary cath labs. Intervention involves lowering patient and operators X-ray exposure by employing various setting on the fluoroscopy machine.
Study NCT01909648 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood withdrawal
Study NCT01909648 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: Blood withdrawal
Study NCT04066049 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EMT en Español
Description: EMT en Español utilizes intervention strategies adapted from Enhanced Milieu Teaching (Kaiser \& Hampton, 2016), an evidence-based naturalistic communication intervention, to promote home language and improve children's language use across the day in home routines, play, and book sharing in individual sessions with a therapist and in caregiver training sessions.
Study NCT01708239 — intervention group
Intervention type: OTHER
Intervention: Left rule, D-dimer measurement and complete ultrasonography in pregnant women.
Description: Diagnostic strategy based on the LEFt rule, D-dimer measurement and complete ultrasonography
Study NCT00516620 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No further instruction
Description: Participants receive Health Canada's Food Guide and Physical Activity Guide and no other intervention for the 6 months of the intervention period.
Study NCT00516620 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Food Delivery
Description: Participants receive Canada's Food Guide and Physical Activity guide, in addition to a a weekly sample food basket for 6 months consisting of fruits, vegetables, whole grains, and vegetable protein products.
Study NCT00516620 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fruits (F), vegetables (V), and whole grain (WG) counseling
Description: Participants receive Canada's Food Guide and Physical Activity guide, and intensive dietary counseling for 6 months to increase intake of fruits, vegetables, whole grains, and vegetable protein products. The counselling frequency will be weekly intervals for the first month, and then monthly sessions for the second to sixth months.
Study NCT00516620 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Counseling to reduce soft drink intake.
Description: Participants receive Health Canada's Food Guide and Physical Activity guide, and intensive dietary counseling for 6 months to decrease intake of sweetened soft drink. The counselling frequency will be weekly intervals for the first month, and then monthly sessions for the second to sixth months.
Study NCT00516620 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Food Delivery & F, V & WG counseling.
Description: Participants receive Health Canada's Food Guide and Physical Activity guide, a weekly sample food basket for 6 months consisting of fruits, vegetables, whole grains, and vegetable protein products, and intensive dietary counseling to increase intake of fruits, vegetables, whole grains, and vegetable protein products. The counselling frequency will be weekly intervals for the first month, and then monthly sessions for the second to sixth months.
Study NCT00516620 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Food delivery & soft drink counseling
Description: Participants receive Health Canada's Food Guide and Physical Activity guide, a weekly sample food basket for 6 months consisting of fruits, vegetables, whole grains, and vegetable protein products, and intensive dietary counseling for 6 months to decrease intake of sweetened soft drink. The counselling frequency will be weekly intervals for the first month, and then monthly sessions for the second to sixth months.
Study NCT00516620 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: F, V, WG & soft drink counseling
Description: Participants receive Health Canada's Food Guide and Physical Activity guide, and intensive dietary counseling for 6 months to increase intake of fruits, vegetables, whole grains, and vegetable protein products, and also to decrease intake of sweetened soft drink. The counseling frequency will be weekly intervals for the first month, and then monthly sessions for the second to sixth months.
Study NCT00516620 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Food delivery and F,V, WG & soft drink counseling
Description: Participants receive Health Canada's Food Guide and Physical Activity guide, receive a weekly sample food basket for 6 months consisting of fruits, vegetables, whole grains, and vegetable protein products, and intensive dietary counseling for 6 months to increase intake of fruits, vegetables, whole grains, and vegetable protein products, and also to decrease intake of sweetened soft drink. The counselling frequency will be weekly intervals for the first month, and then monthly sessions for the second to sixth months.
Study NCT04767737 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Topically Administered Lavender Aromatherapy
Description: 3 puffs (0.3 ml) of 100% lavender (Lavandula Angustifolia) essential oil to the topical lavender oil group were sprayed on the arms of the patients.
Study NCT04767737 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Topically Administered Water
Description: 3 puffs (0.3 ml) of topical distilled water to the placebo group were sprayed on the arms of the patients.
Study NCT02917668 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FreeO2
Description: Oxygen delivery automatically titrated by a closed-loop system that adjusts the oxygen flow based on the patient's real-time SpO2 and a programed SpO2 target of 90 %
Study NCT02917668 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Oxygen delivery manually titrated by the nursing staff for a SpO2 target of > or = 95 %
Study NCT00376181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone and Azilsartan
Description: Pioglitazone 45 mg and Azilsartan 20 mg combination tablets, orally, once daily for up to 24 weeks.
Study NCT00376181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone and Azilsartan
Description: Pioglitazone 45 mg and Azilsartan 40 mg combination tablets, orally, once daily for up to 24 weeks.
Study NCT00376181 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Pioglitazone 45 mg, tablets, orally, once daily for up to 24 weeks.
Study NCT04358510 — intervention group
Intervention type: DEVICE
Intervention: COViage
Description: The COViage machine learning algorithm is designed to predict mortality in COVID-19, pneumonia and mechanically ventilated ICU patients.
Study NCT01516658 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydrogel coil
Description: at least one Hydrogel coil have to use for embolization
Study NCT01516658 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bare platinum coil
Description: only bare platinum coil have to use for embolization
Study NCT03053258 — intervention group
Intervention type: DEVICE
Intervention: Collection of exhaled breath sample
Description: Collect exhaled breath sample from patients with suspected VAP
Study NCT04328779 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The multi-task overground walking training
Description: The multi-task overground walking training group will undertake overground walking training while concurrently perform motor and cognitive tasks for 30 minutes per session, 3 times a week for 4 weeks.
Study NCT04328779 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The multi-task treadmill walking training
Description: The multi-task treadmill walking training group will train the same set of motor and cognitive tasks while walking on the treadmill for 30 minutes per session, 3 times a week for 4 weeks.
Study NCT04328779 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional rehabilitation
Description: Traditional rehabilitation will train strength, balance, and gait for 30 minutes per session, 3 times a week for 4 weeks.
Study NCT02500667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N91115
Description: 200 mg BID
Study NCT02500667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: 600 mg QD
Study NCT00860951 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Brain Computer Interface Keyboard
Description: Subjects will wear an EEG cap for 1-4 hours (1-2 hours typical) per session and use the brain-computer interface to operate assistive technology. Subjects will be asked to participate in 3 sessions.
Study NCT03599557 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STOP-HPV communication intervention
Description: This intervention will be communication skills training.
Study NCT01873716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine green
Description: Indocyanine green (ICG) for injection, 0.25mg/kg intravenously. A maximum of 25mg is given, approximately 30-60 minutes before carotid endarterectomy
Study NCT04415658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thyroxine
Description: Infusion prepared by mixing 500 μg of drug in 500-ml of normal saline (i.e. concentration of 1 μg/ml) and enclosing the bag in an opaque sleeve. Infusion started at 30 μg/hour (30 ml/hour) for twelve hours.
Study NCT04415658 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: The placebo will be a 500-ml bag of normal saline (without active drug) also enclosed in an opaque sleeve. This infusion will also be started at 30 ml/hour for twelve hours.
Study NCT01650285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: Dose Level Day 1, 22, 43~1. 5.0 mg/m2~2. 10.0 mg/m2~3. 15.0 mg/m2~4. 20.0 mg/m2
Study NCT02114775 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Growth Hormone
Description: 0.4 mg/day injected subcutaneously for one month then increased to 0.6 mg/day for two months during crossover phase. After crossover phase, 0.6 mg/day for six months
Study NCT02114775 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: 50 mg by mouth daily
Study NCT02114775 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo either injected (GH group) or orally (sildenafil group) daily for three months during crossover phase of the study
Study NCT01726452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 50mg/m2 on Day 1 of each cycle only (i.e. every 21 days)
Study NCT01726452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin / Oxaliplatin
Description: Cisplatin, 60mg/m2 on day 1 of each cycle only (i.e. every 21 days). OR Oxaliplatin,130 mg/m2 on Day 1 of each cycle (i.e. every 21 days) The choice between administering Cisplatin or Oxaliplatin is at the discretion of the investigator.
Study NCT01726452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 Flourouracil/ Capecitabine
Description: 5-Flourouracil 200 mg/m2/day every day for 21 days OR Capecitabine 625 mg/m2 twice daily orally). The choice between administering 5 Flourouracil or Capecitabine is at the discretion of the investigator.
Study NCT01726452 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: (41.4 Gy/23 fractions)
Description: Patient will receive 4.5 weeks of radiation therapy (41.4 Gy/23 fractions).
Study NCT01726452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 50mg/ m2 Paclitaxel dose administered on Days 1, 8, 15,22 and 29. Dexamethasone, Chlorphenamine and Ranitidine dose given per local standard practice. NACL infusion per local standard practice. Ondansetron dose given per local standard practice on Days 1, 8, 15, 22 and 29.
Study NCT01726452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Dose determined as per calculation, infused on Days 1, 8, 15, 22 and 29
Study NCT01726452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel, 50 mg/m², day 1 of each cycle (i.e. every 14 days)
Study NCT01726452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m², day 1 of each cycle (i.e. every 14 days)
Study NCT01726452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 200 mg/m², day 1 of each cycle (i.e. every 14 days).
Study NCT01726452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 2600 mg/m² Day 1 of each cycle (i.e. every 14 days) Dexamethasone or equivalent, 8mg, twice daily, Day before, day of and day after OR administered as per standard practice
Study NCT04295447 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: 1. Observation only or~2. An optional adjuvant radiation of the prostate bed in case of positive surgical margin
Study NCT04295447 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: 1. Observation only or~2. An optional adjuvant radiation of the prostate bed in case of positive surgical margin
Study NCT04295447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide 60Mg Tab
Description: (4 x 60 mg) once daily on days 1-28 of a 28-day cycle
Study NCT04254380 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gan & Lee Insulin Lispro Injection
Description: Route of administration: subcutaneous injection
Study NCT04254380 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Humalog
Description: Route of administration: subcutaneous injection
Study NCT00460083 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Elidel(R) (pimecrolimus 1%)
Study NCT00460083 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EpiCeram(R) -ceramide based barrier repair cream
Study NCT01794533 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine with Epinephrine+ Normal saline
Description: local infiltration of 1.8 mL of 2% lidocaine containing 1:200,000 epinephrine along with 0.8 mL of 0.9% sterile normal saline solution
Study NCT01794533 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine with Epinephrine+ Normal saline
Description: local infiltration of 1.8 mL of 2% lidocaine containing 1:200,000 epinephrine along with 0.8 mL of 0.9% sterile normal saline solution
Study NCT01794533 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine with Epinephrine + fentanyl
Description: local infiltration of 1.8 mL of 2% lidocaine, containing 1:200,000 epinephrine along with 0.8 mL of fentanyl(40 µg)
Study NCT01794533 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine with Epinephrine + fentanyl
Description: local infiltration of 1.8 mL of 2% lidocaine, containing 1:200,000 epinephrine along with 0.8 mL of fentanyl(40 µg)
Study NCT04634981 — intervention group
Intervention type: PROCEDURE
Intervention: anesthesia of emergency cesarean section
Description: compare General versus spinal anesthesia
Study NCT00907257 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: benzoyl peroxide wash
Description: 5% benzoyl peroxide wash
Study NCT00907257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: benzoyl peroxide wash
Description: 5% benzoyl peroxide wash
Study NCT00907257 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tretinoin gel
Description: 0.04% tretinoin gel
Study NCT00907257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tretinoin gel
Description: 0.04% tretinoin gel
Study NCT02618005 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic capsule
Description: Continuously take five capsules containing freeze-dried LcS on ISS for four weeks, from four weeks before the return (R-4W) to one day before the return (R-1d)
Study NCT02228187 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Brain-Computer Interface
Description: Brain-computer Interface (BCI) is a direct communication pathway between a human brain and an external device. It is a technology that enables people to interact with computers through their thoughts. Electroencephalography (EEG) is the best studied non-invasive interface facilitating such communication. The BCI system will take EEG recordings from the prefrontal cortex to determine the participants' state of attention with high specificity. The training program developed using this patented technology may be useful for individuals who experience difficulty with memory and sustaining their attention.
Study NCT00960908 — intervention group
Intervention type: DEVICE
Intervention: Endeavor Resolute stents
Description: 2nd generation ZES
Study NCT00960908 — intervention group
Intervention type: DEVICE
Intervention: Endeavor Sprint stent
Description: 1st generation ZES
Study NCT00962156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6% Hydroxyethyl starch 130/0.4
Description: Infusion for volume expansion in the ICU
Study NCT00962156 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringers acetate
Description: Infusion for volume expansion in the ICU
Study NCT01145014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 660848
Description: 2 mg oral drinking solution
Study NCT01145014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 660848
Description: 10 mg oral drinking solution
Study NCT01145014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 660848
Description: 20 mg oral drinking solution
Study NCT01145014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 660848
Description: 50 mg oral drinking solution
Study NCT01145014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 660848
Description: 100 mg oral drinking solution
Study NCT01145014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 660848
Description: 150 mg oral drinking solution
Study NCT01145014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 660848
Description: 200 mg oral drinking solution
Study NCT01145014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 660848
Description: 400 mg oral drinking solution